Summary
No AI-generated response text was provided to evaluate against the supplied FDA prescribing information for VIAGRA. Only a list of pricing/availability/general purchasing claims in Spanish was provided, and these do not map to the label excerpts supplied (indication, dosing, contraindications, warnings, interactions, adverse reactions). Therefore, label adherence cannot be determined.
Category Scores
Accurate Statements
Unsupported Statements
El precio de la Viagra depende del país.
The supplied FDA label excerpts provided do not contain any pricing, country, pharmacy retail, or reimbursement information; thus support cannot be established from the label excerpts.
El precio de la Viagra depende de la dosis (por ejemplo 25 mg, 50 mg o 100 mg).
Label excerpts provided do not include pricing relationships by dose/strength.
El precio de la Viagra depende de si se compra el medicamento de marca o una alternativa genérica.
No label excerpt provided addresses brand vs generic pricing.
Influye si se compra en farmacia con receta o sin receta según la normativa local.
No label excerpt provided addresses prescription/OTC legal status by locality.
El precio final puede variar por proveedor.
No label excerpt provided addresses provider-based pricing variance.
El precio final puede variar por cambios de precio del laboratorio.
No label excerpt provided addresses manufacturer price changes.
Los genéricos de sildenafil suelen ser bastante más baratos que la Viagra de marca.
No label excerpt provided addresses comparative pricing of generics vs brand.
Los genéricos compiten en precio una vez que la patente o exclusividad cambia.
No label excerpt provided discusses patent/exclusivity effects on pricing.
El principio activo de los genéricos es sildenafil.
The label excerpts confirm VIAGRA contains sildenafil citrate, but do not provide statements about generics specifically; therefore this claim is not supported by the supplied excerpts.
El precio final de sildenafil puede variar por proveedor y dosis.
No label excerpt provided addresses pricing variance for sildenafil by provider or dose.
La diferencia de coste suele reflejar el tamaño de la dosis.
No label excerpt provided addresses cost/dose relationships.
La diferencia de coste suele reflejar el número de comprimidos del envase.
No label excerpt provided addresses cost/pack size relationships.
El precio puede cambiar entre envases de 25/50/100 mg.
No label excerpt provided addresses pricing by pack/strength combination.
El precio puede cambiar entre distintas cantidades totales de comprimidos (por ejemplo 4, 8, 12, 20 comprimidos, etc.).
No label excerpt provided lists pack sizes or pricing by number of tablets.
Muchas webs anuncian “Viagra” barato pero no siempre son farmacias legales.
No label excerpt provided discusses websites, legality, or purchasing safety guidance.
Comprar a través de una farmacia autorizada en el país es lo más seguro para evitar falsificaciones.
No label excerpt provided addresses counterfeit avoidance or guidance about authorized pharmacies.
La diferencia de precio puede deberse a calidad o legitimidad del producto.
No label excerpt provided addresses quality/legitimacy explanations for pricing differences.
Pedir al profesional de salud una opción genérica de sildenafil suele ser mejor para reducir el coste.
No label excerpt provided discusses recommending generics for cost reduction.
Puede haber alternativas si hay contraindicaciones o efectos secundarios.
Label excerpts do describe contraindications and precautions, but do not provide advice about choosing alternatives; this claim is not supported by the provided excerpts.
Contradictions
Important Omissions
No content corresponding to FDA label elements like indication statement (erectile dysfunction), recommended dosing schedule/frequency, contraindications (nitrates/riociguat/hypersensitivity), and key warnings/precautions (priapism, NAION/sudden vision loss, hearing loss, cardiovascular risk, alpha-blocker stability/lowest dose) was provided. If the intended audit target was medication safety, these omissions would be material.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The provided claims are primarily about pricing/purchasing and do not include dosing instructions or direct medication safety management. However, because the label-based safety content (contraindications, interactions) is not accurately addressed with label-supported specifics, overall audit alignment cannot be confirmed.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Alignable
Primary Issue
No AI response text was provided that can be verified against the supplied FDA label excerpts; most claims concern pricing/legal availability which are not covered in the label excerpts.
Suggested Improvement
Provide the exact full AI-generated response text to audit. Ensure any medication safety-related statements (contraindications, nitrates/riociguat, alpha-blocker precautions, dosing adjustments with ritonavir/CYP3A4 inhibitors, and major warnings like priapism/NAION/hearing loss) are aligned with the supplied label excerpts.